Welcome to our dedicated page for Lipocine SEC filings (Ticker: LPCN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lipocine Inc. (LPCN) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, including current reports, quarterly and annual reports, and exhibits filed with the U.S. Securities and Exchange Commission. According to recent Form 8‑K filings, Lipocine uses these reports to announce clinical and corporate developments such as Phase 3 trial progress, data presentations, and financial results.
Current reports on Form 8‑K have documented events including enrollment and interim safety milestones in the Phase 3 clinical trial of LPCN 1154 for postpartum depression, presentation of LPCN 2101 data at the American Epilepsy Society annual meeting, and presentation of LPCN 2401 clinical data at ObesityWeek. Other 8‑K filings reference updated corporate presentations and the company’s participation in investor conferences, as well as press releases announcing quarterly financial and operational results.
Lipocine’s periodic reports on Forms 10‑Q and 10‑K, referenced in its press releases, provide more detailed information on revenues from TLANDO licensing and royalties, research and development expenses related to candidates such as LPCN 1154 and LPCN 2401, general and administrative costs, and cash and investment balances. These filings also include risk factor discussions and forward‑looking statements that describe uncertainties around clinical trials, regulatory approvals, partnering, and commercialization.
On Stock Titan, investors can review Lipocine’s SEC filings in one place and use AI‑powered summaries to interpret dense disclosures. Real‑time updates from EDGAR allow users to see new 8‑K, 10‑Q, and 10‑K filings as they appear, while Form 4 and related insider transaction reports can be accessed to monitor trading by Lipocine’s officers and directors. AI tools help highlight key points from lengthy documents, such as clinical program updates, revenue drivers from TLANDO agreements, and changes in operating expenses, giving a clearer view of how Lipocine’s oral drug development strategy is reflected in its official regulatory record.
Lipocine Inc. filed a current report to announce that the company will present and meet with investors at the H.C. Wainwright 27th Annual Global Investor Conference. The event is scheduled for September 8–10, 2025, in New York City. The company furnished a press release with additional details as Exhibit 99.1 to the report.
Lipocine Inc. filed an 8-K reporting a material event: the company submitted a presentation as Exhibit 99.1 for the H.C. Wainwright 27th Annual Global Investor Conference and included the interactive cover page Exhibit 104 in Inline XBRL format. The filing is signed by Mahesh V. Patel, President and Chief Executive Officer, and is dated September 5, 2025. The filing does not include earnings, financial tables, or other material transaction disclosures; it documents public investor-facing presentation materials being made available.
Lipocine Inc. reported that scientific abstracts related to its program designated LPCN 2101 have been accepted for presentation at the 2025 American Epilepsy Society annual meeting. The conference is scheduled for December 5–9, 2025, in Atlanta, Georgia. Lipocine furnished the related press release as Exhibit 99.1 to this report.
Lipocine Inc. (LPCN) – Q2 2025 10-Q snapshot
For the quarter ended 30 Jun 2025, revenue jumped to $0.623 M (vs $0.090 M LY) on a one-time $0.5 M license payment from newly signed partners, offsetting lower royalties. Operating expenses fell 10% YoY to $3.0 M, led by a 41% drop in G&A, but R&D rose 14% to support LPCN 1154 and other pipeline programs. Net loss narrowed to $2.21 M (-$0.41 EPS) from -$3.07 M (-$0.57 EPS).
Six-month results were weaker: revenue fell 91% YoY to $0.717 M as the prior-year period contained a $7.5 M Verity up-front; net loss swung to $4.07 M (-$0.76 EPS) from a $0.45 M profit. Operating cash burn was $3.9 M; cash & treasury bills ended at $18.6 M (cash $6.0 M, securities $11.9 M) versus $22.5 M 12/31/24. Management projects liquidity through at least Aug 2026 but continues to access an ATM facility (23,739 shares sold for $0.08 M during Q2).
- Total liabilities remain low at $1.45 M; equity fell to $17.1 M.
- New Aché license (Brazil) plus earlier SPC (South Korea) and Pharmalink (GCC) deals expand TLANDO ex-US footprint; up to $259 M in contingent milestones remain unrealized.
- Authorized shares cut to 75 M; 5.42 M shares outstanding.
- No warrants outstanding after 2019/2020 series expired.
Outlook: Near-term revenue hinges on additional license milestones and TLANDO royalties; continued pipeline spend and limited cash generation imply further equity or partnership funding before 2026.
On 9 July 2025 Lipocine Inc. (NASDAQ: LPCN) filed a Form 8-K under Item 8.01 – Other Events. The sole disclosure is that the company hosted a virtual key-opinion-leader (KOL) event focused on LPCN 1154 (BRLIZIO™) as a potential treatment for postpartum depression. A webcast link and slide deck are available on the corporate website, and the materials have been furnished as Exhibit 99.1.
Under Item 9.01 the filing lists Exhibit 104 (Inline XBRL cover page). No financial metrics, clinical trial results, or transactional details accompany the notice. The document is signed by President & CEO Mahesh V. Patel.
This 8-K signals continued development and external engagement around LPCN 1154 but provides no new quantitative data likely to affect near-term valuation.
Lipocine (NASDAQ:LPCN) filed an 8-K announcing that the first patient has been dosed in its Phase 3 clinical trial of LPCN 1154 for postpartum depression. The disclosure, furnished under Item 8.01 with the press release attached as Exhibit 99.1, marks the transition of LPCN 1154 into late-stage development—an essential step toward potential NDA submission and commercialization. No changes to financial guidance, funding, or corporate strategy were reported, and Items 2.02, 5.02 or other sections were not included. While the filing contains no revenue figures, the milestone may accelerate future catalysts such as data read-outs, regulatory meetings and partnership discussions that could materially influence valuation.